1. Home
  2. DQ vs OMER Comparison

DQ vs OMER Comparison

Compare DQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DAQO New Energy Corp.

DQ

DAQO New Energy Corp.

HOLD

Current Price

$12.31

Market Cap

877.0M

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$21.05

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DQ
OMER
Founded
2006
1994
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.0M
844.6M
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
DQ
OMER
Price
$12.31
$21.05
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$28.91
$32.50
AVG Volume (30 Days)
782.6K
1.4M
Earning Date
04-29-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
$69.82
N/A
Revenue Next Year
$34.34
$233.22
P/E Ratio
N/A
$24.01
Revenue Growth
N/A
N/A
52 Week Low
$11.17
$4.06
52 Week High
$36.59
$19.65

Technical Indicators

Market Signals
Indicator
DQ
OMER
Relative Strength Index (RSI) 42.23 66.21
Support Level $11.47 $18.00
Resistance Level $12.55 N/A
Average True Range (ATR) 0.43 0.83
MACD -0.01 -0.18
Stochastic Oscillator 42.19 86.14

Price Performance

Historical Comparison
DQ
OMER

About DQ DAQO New Energy Corp.

Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: